Holds up
“GLP-1 dosing errors are flooding poison control”
The count survives. The word “poisoned” doesn’t.
Researchers pulled every human GLP-1 exposure reported to U.S. poison centers from 2012 through 2023 — 10,033 of them — and cut the data at July 2021, when semaglutide was approved for weight loss (Miller et al., J Med Toxicol, 2026). Before: 3,113 calls. After: 6,920, with semaglutide alone accounting for 64.2% of them. The callers skewed younger and more female. And the climb wasn’t drift — a segmented model found semaglutide calls rising an additional 9.9% per quarter after the approval, while the share sent on to a healthcare facility went from 23.0% to 33.5%.
Here’s the step the headlines skip: where the errors come from. Most of these calls weren’t overdoses. They were unintentional therapeutic errors — someone got the amount wrong. The FDA has a standing alert on compounded injectable semaglutide for exactly this: a vial, a syringe, and a patient doing the arithmetic themselves, with milliliters and milligrams and “units” all in play and no auto-calibrated pen to catch a slip.
The verdict: the claim holds up. Calls rose, the rise is statistically solid, and the referral bump is real. What doesn’t hold up is the picture the word “poisoned” paints — the study’s own finding is that the clinical effects were generally mild, mostly gastrointestinal. A real safety signal got louder in translation.
